Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinggan Liangxue Jiedu decoction (QGLXJD) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Institute of Traditional Chinese Medicine for the treatment of psoriasis vulgaris, specifically the "blood heat syndrome" pattern. The decoction is designed to "clear liver fire," "cool the blood," and "remove toxins," which are central concepts in TCM for managing acute inflammatory skin conditions. Mechanistically, QGLXJD has been shown to modulate the neuro-endocrine-immune axis by reducing the expression of pro-inflammatory neuropeptides such as Substance P (SP) and Vasoactive Intestinal Peptide (VIP), as well as regulating the balance of Th1/Th17 cytokines. It is primarily administered as an oral decoction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinggan Liangxue Jiedu decoction.